The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer

Data reported as no. (%) unless otherwise indicated.
^aHT criteria: chronic lymphocytic thyroiditis on histopathology and/or elevated thyroperoxidase antibodies and/or diffuse heterogeneity on ultrasound.

Abbreviations: AUS, atypia of undetermined significance; FLUS, follicular lesion of undetermined significance; SFN, suspicious for follicular or Hürthle cell neoplasm; SUSP, suspicious for malignancy.
^a P value for 2 × 6 χ ² analysis of six TBSRTC categories.

Abbreviations: FTC, follicular thyroid cancer; MTC, medullary thyroid cancer; PTC, papillary thyroid cancer.

Abbreviations: AUS, atypia of undetermined significance; FLUS, follicular lesion of undetermined significance; SFN, suspicious for follicular or Hürthle cell neoplasm; SUSP, suspicious for malignancy.
^aPatients with more than one evaluable nodule were classified according to the highest TBSRTC score of the multiple nodules.
^bThyroid cancer was defined using histopathology as well as TBSRTC 6 cytology in cases where surgery did not occur.

Data reported as no. (%) unless otherwise indicated.
^aMultifocal: two or more nodules each ≥1 cm.

Authors and Disclosures

Nathalie Silva de Morais^1,2,3*, Jessica Stuart¹*, Haixia Guan^1,4, Zhihong Wang^1,5, Edmund S. Cibas¹, Mary C. Frates¹, Carol B. Benson¹, Nancy L. Cho¹, Mathew A. Nehs¹, Caroline A. Alexander¹, Ellen Marqusee¹, Mathew I. Kim¹, Jochen H. Lorch¹, Justine A. Barletta¹, Trevor E. Angell¹ and Erik K. Alexander<sup>1

1</sup>Thyroid Interdisciplinary Team, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115; ²Endocrinology Service, Instituto Nacional de Câncer and Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil 21941–902; ³Endocrinology Service, Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione, Rio de Janeiro, Brazil 20211–340; ⁴Department of Endocrinology and Metabolism, The First Hospital of China Medical University, Shenyang, China 110001; and ⁵Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, China 110001
*N.S.M and J.S. contributed equally to this study.

Correspondence
Nathalie Silva de Morais, MD, Harvard Institute of Medicine, Thyroid Section, 77 Avenue Louis Pasteur, Suite 641, Boston, Massachussetts 02115. E-mail: nathalieaos@gmail.com.

Disclosure Summary
J.H.L. has received research support from Bristol-Myers Squibb, Bayer; and Novartis; and consulting fees from Bayer, Genentech, and Eisai. The remaining authors have nothing to disclose.